Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 6/20 | 0.33 |
| ▸ | CDK8 | P49336 | 6/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | MYLK | Q15746 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | CILK1 | Q9UPZ9 | 1/20 | 0.32 |
| ▸ | CDK11A | Q9UQ88 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6215881 | 0.89 | CCNC (0.33) | CCNCCDK8FLT3MYLKAURKB | |
| SCHEMBL6213830 | 0.82 | TSHR (0.32) | — | |
| SCHEMBL4828770 | 0.76 | MAPT (0.31) | — | |
| SCHEMBL221826 | 0.75 | OPRM1 (0.33) | — | |
| SCHEMBL6212520 | 0.72 | TSHR (0.30) | — | |
| SCHEMBL7102996 | 0.72 | OPRD1 (0.31) | SLC22A12 | |
| SCHEMBL2103475 | 0.72 | TSHR (0.33) | — | |
| SCHEMBL6214453 | 0.72 | OPRD1 (0.31) | — | |
| SCHEMBL2626833 | 0.69 | IDH1 (0.31) | — | |
| SCHEMBL2103249 | 0.69 | IDH1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0975602-B1 | IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND USES THEREOF | GRUENENTHAL GMBH (DE) | 2005-06-15 | — | — | EP | disclosed |
| US-6777426-B2 | SELECTIVE AGONISTS FOR HUMAN ALPHA 2 ADRENERGIC RECEPTORS; TREATING PAIN, MIGRAINE, HEADACHES, GLAUCOMA; 2-(INDAN-5-YL)AMINO-2-IMIDAZOLINE FOR EXAMPLE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-08-17 | — | — | US | disclosed |
| EP-0975602-A4 | IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND USES THEREOF | GRUENENTHAL GMBH (DE) | 2003-01-22 | — | — | EP | disclosed |
| US-20020019390-A1 | Imidazole and imidazoline derivatives and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-02-14 | — | — | US | disclosed |
| US-6294566-B1 | ENANTIOMORPHS REVERSE AND ADRENERGIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-09-25 | — | — | US | disclosed |
| US-6093727-A | A SELECTIVE AGONISTS FOR HUMAN ALPHA 2 RECEPTORS FOR TREATING DISORDERS AS HYPERTENSION, PAIN, GLAUCOMA, ALCOHOL AND DRUG WITHDRAWAL, ISCHEMIA, RHEUMATOID ARTHRITIS, MIGRAINE, COGNITIVE DEFICIENCY, SPASTICITY, DIARRHEA, NASAL CONGESTION | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-07-25 | — | — | US | disclosed |
| EP-0975602-A1 | IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-02-02 | — | — | EP | disclosed |
| US-5866579-A | SELECTIVE AGONISTS FOR CLONED HUMAN ALPHA-2 ADRENERGIC RECEPTORS. | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998046572-A1 | IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019390-A1 | Imidazole and imidazoline derivatives and uses thereof | ADRB2, ADRA2C, ADRB3 | CCNC 4128/4885CDK8 3126/4885FLT3 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.